bell
The current prices are delayed by 15 mins, login to check live prices.
Neuland Laboratories Ltd share price logo

Neuland Laboratories Ltd

(NEULANDLAB)

₹175961.4%

as on 04:01PM, 06 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Neuland Laboratories Ltd Analyst Rating

based on 2 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts offering long term price targets for Neuland Laboratories Ltd. An average target of ₹17625

Source: S&P Global Market Intelligence

Neuland Laboratories Ltd Share analysis

Neuland Laboratories Ltd price forecast by 2 analysts

Upside of0.16%

High

₹20000

Target

₹17625.00

Low

₹15250

Neuland Laboratories Ltd target price ₹17625, a slight upside of 0.16% compared to current price of ₹17596. According to 2 analysts rating.

Source: S&P Global Market Intelligence

Neuland Laboratories Ltd Performance

  • Day's Low

    Day's High

    ₹17,500
    ₹17,946.35
  • 52 Week's Low

    52 Week's High

    ₹4,926.05
    ₹18,100
1 Month Return+ 27.7 %
3 Month Return+ 39.21 %
1 Year Return+ 246.3 %
Previous Close₹17,846.35
Open₹17,885.05
Volume17.79K
Upper Circuit-
Lower Circuit-
Market Cap₹22,896.67Cr

Neuland Laboratories Ltd Key Statistics

P/E Ratio80.72
PEG Ratio7.7
Market Cap₹22,896.67 Cr
P/B Ratio6.35
EPS232.61
Dividend Yield0.22
SectorPharmaceuticals
ROE26.48

Neuland Laboratories Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
BUY₹22,896.67 Cr820%0.54₹300 Cr₹1,558 Cr
NA₹214.08 Cr213.48%0.58-₹12 Cr₹15 Cr
NA₹905.32 Cr817.04%0.65₹23 Cr₹307 Cr
HOLD₹4,202.80 Cr27.13%0.50₹136 Cr₹623 Cr
BUY₹13,741.09 Cr74.1%0.63₹405 Cr₹4,506 Cr

About Neuland Laboratories Ltd

Neuland Laboratories NLL, a private limited company founded in 1984, manufactures bulk drugs, such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin, which are exported to more than 35 countries. To part finance capacity expansion and diversify its product-mix, NLL made an initial public offering in 1994 for Rs 5.69 crores. The Research & Development has developed a process to manufacture Oflaxacin for Regulatory Markets, and the Pashamylaram unit received USFDA approval for Rantidine Hydrochloride Form. During the years 1992-2000 the company introduced Itraconazole, an antifungal drug, Ipratropium Bromide, an antiasthmatic drug, Mirtrazapine, an antidepressive drug, and Ramipril, a cardiovascular drug, while in 2001 it increased its capacity of Ciprofloxacin and Ranitidine with financial assistance from IDBI of Rs.65 lacs. In 2002, it commenced production of Ramipril and in 2003 of Citalopram Hydrobromide, Pirbuterol Acetate, Levofloxacin and Levetiracetam. Furthermore, Neuland Laboratories Ltd has a subsidiary in Delaware USA and in Japan (2008-2009). Neuland Laboratories NLL is thus well-positioned in the bulk drugs market and is continuously striving to expand its product mix with the help of innovation in research and development.

Share Price: ₹17596.00 per share as on 06 Dec, 2024 04:01 PM
Market Capitalisation: ₹22,896.67Cr as of today
Revenue: ₹310.84Cr as on September 2024 (Q3 24)
Net Profit: ₹32.84Cr as on September 2024 (Q3 24)
Listing date: 17 May, 1995
Chairperson Name: D Saharsh Rao
OrganisationNeuland Laboratories Ltd
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Neuland Laboratories Ltd

  • Neuland Laboratories Reports Mixed Financial Performance - 05 Dec, 2024

    Neuland Laboratories has seen a remarkable 1,655% return over two years, but Q2 FY25 shows a 25.6% revenue drop and a 62.9% decline in net profit. Despite challenges, the company maintains a strong order pipeline and a nearly debt-free status.
  • Neuland Laboratories Stock Soars with Impressive Returns - 16 Nov, 2024

    Neuland Laboratories has seen remarkable growth, with shares rising 202% in the past year and 842% over three years. An investment of Rs 1 lakh three years ago would now be worth Rs 9.32 lakh. The stock has a market cap of Rs 19,947.21 crore and recently rallied nearly 10% to reach an intraday high of Rs 16,142.25.
  • Neuland Laboratories Stock Hits Record High Amid Strong Demand - 12 Nov, 2024

    Neuland Laboratories Ltd. experienced a significant stock surge, reaching a record high of ₹16,544.75, driven by strong investor interest and a key partnership in neuroscience. Despite a decline in quarterly profits, the stock's performance reflects robust market dynamics and investor confidence.
  • Goldman Sachs Optimistic on Neuland Labs Despite Weak Q2 - 07 Nov, 2024

    Neuland Laboratories reported a significant decline in net sales and profit for September 2024. However, Goldman Sachs maintains a buy rating, raising the target price to Rs 15,250, citing long-term growth potential despite recent challenges.
  • Neuland Laboratories Faces Sharp Decline After Q2 Results - 06 Nov, 2024

    Neuland Laboratories reported disappointing Q2 FY25 results, with net sales down 25.59% and PAT declining 63%. The stock fell significantly, reflecting investor concerns over performance.

Insights on Neuland Laboratories Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, NEULANDLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, NEULANDLAB stock has moved up by 27.7%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 25.72% to 26.46% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 97.87 Cr → 32.84 Cr (in ₹), with an average decrease of 66.5% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 34.76% to 34.11% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 4.07% to 4.04% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 465.03 Cr → 315.18 Cr (in ₹), with an average decrease of 32.2% per quarter

  • imgNEGATIVE IMPACT

    Promoter Holding Down

    img

    Promoters have decreased holdings from 32.72% to 32.64% in Sep 2024 quarter

Neuland Laboratories Ltd Financials

Value in ₹ crore
DetailsQ'3 23Q'4 23Q'1 24Q'2 24Q'3 24
Revenue₹417.75Cr (-)₹392.83Cr (↓5.97%)₹385.01Cr (↓1.99%)₹439.60Cr (↑14.18%)₹310.84Cr (↓29.29%)
Net Income₹89.25Cr (-)₹81.39Cr (↓8.81%)₹67.56Cr (↓16.99%)₹97.87Cr (↑44.86%)₹32.84Cr (↓66.45%)
Net Profit Margin21.36% (-)20.72% (↓3.00%)17.55% (↓15.30%)22.26% (↑26.84%)10.56% (↓52.56%)
Value in ₹ crore
Details2021202220232024
Total Assets₹1,333.94Cr (-)₹1,398.85Cr (↑4.87%)₹1,592.85Cr (↑13.87%)₹1,843.65Cr (↑15.75%)
Total Liabilities₹552.06Cr (-)₹563.28Cr (↑2.03%)₹604.49Cr (↑7.32%)₹567.11Cr (↓6.18%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹56.63Cr (-)₹189.28Cr (↑234.24%)₹60.41Cr (↓68.08%)₹238.53Cr (↑294.85%)₹260.06Cr (↑9.03%)

Index Inclusions

BSE Healthcare

₹44,509.74

-0.08 (-34.05%)

BSE Small-Cap

₹57,050.71

0.6 (342.93%)

S&P BSE AllCap

₹10,471.31

0.68 (71.07%)

Neuland Laboratories Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
32.64%
-0.24
Foreign Institutions
26.46%
2.87
Mutual Funds
4.04%
-0.93
Retail Investors
34.11%
-1.86
Others
2.74%
0.91

Neuland Laboratories Ltd Key Indicators

Details20202021202220232024
Return On Equity %2.279.497.8617.926.48
Details20202021202220232024
Return On Assets %1.36.044.5610.2716.28
Details20202021202220232024
Book Value Per Share (₹)549.68608.98650.88769.94993.66
Details20202021202220232024
Earning Per Share (₹)12.5762.549.47126.75232.61

Neuland Laboratories Ltd Valuation

Neuland Laboratories Ltd in the last 5 years

  • Overview

  • Trends

Lowest (10.19x)

March 30, 2020

Industry (57.44x)

December 6, 2024

Today (80.72x)

December 6, 2024

Highest (81.87x)

December 5, 2024

LowHigh

Neuland Laboratories Ltd Earnings and Dividends

  • Neuland Laboratories Ltd Earnings Results

    Neuland Laboratories Ltd’s net profit fell -63.2% since last year same period to ₹32.84Cr in the Q2 2024-2025. On a quarterly growth basis, Neuland Laboratories Ltd has generated -66.45% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Neuland Laboratories Ltd Dividends May,2024

    In the quarter ending March 2024, Neuland Laboratories Ltd has declared dividend of ₹14 - translating a dividend yield of 0.14%.

    Read More about Dividends

Neuland Laboratories Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Neuland Laboratories Ltd is currently in a Bullish trading position according to technical analysis indicators.

FAQs on Neuland Laboratories Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Neuland Laboratories Ltd shares.

Neuland Laboratories Ltd (NEULANDLAB) share price today is ₹17596

Neuland Laboratories Ltd is listed on NSE

Neuland Laboratories Ltd is listed on BSE

  • Today’s highest price of Neuland Laboratories Ltd is ₹17946.35.
  • Today’s lowest price of Neuland Laboratories Ltd is ₹17500.

PE Ratio of Neuland Laboratories Ltd is 80.72

PE ratio = Neuland Laboratories Ltd Market price per share / Neuland Laboratories Ltd Earnings per share

Today’s traded volume of Neuland Laboratories Ltd(NEULANDLAB) is 17.79K.

Today’s market capitalisation of Neuland Laboratories Ltd(NEULANDLAB) is ₹22896.67Cr.

Neuland Laboratories Ltd(NEULANDLABPrice
52 Week High
₹18100
52 Week Low
₹4926.05

Neuland Laboratories Ltd(NEULANDLAB) share price is ₹17596. It is down -2.78% from its 52 Week High price of ₹18100

Neuland Laboratories Ltd(NEULANDLAB) share price is ₹17596. It is up 257.20% from its 52 Week Low price of ₹4926.05

Neuland Laboratories Ltd(NEULANDLABReturns
1 Day Returns
-250.35%
1 Month Returns
27.7%
3 Month Returns
39.21%
1 Year Returns
246.3%